{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-22-000007","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2022-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.740614+00:00","generated_at":"2026-06-26T04:30:36.314089+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Edwards Q1 sales $1.34B (+13% underlying), adjusted EPS $0.60; TAVR up 14% underlying","bullets":["Q1 sales $1.34B, up 10% reported (13% underlying); adjusted EPS $0.60.","TAVR sales $881M (+11% reported, +14% underlying); global TAVR opportunity seen doubling to $10B by 2028.","Full-year 2022 guidance: sales $5.5-6.0B, adjusted EPS $2.50-$2.65; Q2 sales $1.36-1.44B.","MITRIS RESILIA valve for mitral position received US FDA approval and launched commercially.","Repurchased ~$400M stock in Q1; free cash flow $221M; cash $1.5B."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-22-000007","json":"https://secwatch.observer/filing/0001099800-22-000007.json","markdown":"https://secwatch.observer/filing/0001099800-22-000007.md","text":"https://secwatch.observer/filing/0001099800-22-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980022000007/0001099800-22-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980022000007/ew-20220426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:30:36.314089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}